VIDA Named One of the Fastest-Growing Private Companies in the US

August 21, 2023 11:00 PM AEST | By EIN Presswire

Google News:

VIDA Named One of the Fastest-Growing Private Companies in the US — Image source: Kalkine Media

Recent News

ASX 200 Slips as Labour Data and US Rate Decision Shape Market

Berenberg initiates coverage of these two mid-cap U.K. names

Energy Sector Leads Market Turnaround on ASX 300 Index

CBA Leads ASX 200 Surge Amid Global Flows and Index Focus

VIDA Included on the Prestigious 2023 Inc. 5000 list

We are at the forefront of a transformative data revolution in pharmaceutical trials.”

— Susan Wood, PhD

CORALVILLE, IA, USA, August 21, 2023/EINPresswire.com/ -- VIDA Diagnostics, Inc. (VIDA), the leader in clinical imaging intelligence, today announced that it has been featured in the annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. VIDA experienced significant revenue growth over the past three years because of increasing demand for its digital biomarkers and trial imaging management solutions that accelerate the approval and adoption of life-saving therapies to patients.

“We are proud to earn recognition as one of the fastest growing companies in the US, said Susan Wood, PhD, CEO of VIDA. “We are at the forefront of a transformative data revolution in pharmaceutical trials. The drive towards high-quality, imaging-based digital biomarkers is accelerating therapy pipelines and our solution is a perfect fit to meet this demand. ”

VIDA has proven the value of its digital imaging biomarker solution, which includes a comprehensive suite of imaging biomarkers, with trial imaging management software services to optimize data quality and operational efficiency. The solution is offered through an AI-powered cloud platform, which has empowered over 1,000 trial sites in less than two years since its introduction. VIDA is continuing its rapid expansion, enabling more clinical trial sponsors to reap the benefits of digital biomarkers, effective trial imaging operations, and faster approval of therapeutics to patients in need.

“Running a business has only gotten harder since the end of the pandemic,” says Inc. editor-in-chief Scott Omelianuk. “To make the Inc. 5000—with the fast growth that requires—is truly an accomplishment. Inc. is thrilled to honor the companies that are building our future.”

The 2023 Inc. 5000 list measures revenue growth from 2019 through 2022. To qualify, companies must be U.S.-based and privately held, independent – not subsidiaries or divisions of other companies. Complete results of the Inc. 5000 can be found at inc.com/inc5000.

About VIDA
VIDA is a clinical imaging intelligence company that is accelerating the development of life-saving therapies to patients through an AI-powered digital biomarker solution. With proprietary imaging biomarkers for precise quantitative endpoints and a trial imaging management solution, the VIDA Intelligence Platform is helping biopharma sponsors save millions in drug development costs. VIDA’s software is FDA cleared, CE-marked, Health Canada licensed, TGA registered, and PMDA certified for clinical use in the U.S., European Economic Area, Canada, Australia, and Japan. Learn more at https://vidalung.ai. Follow @vidalung on Twitter and LinkedIn.

Marcel Nienhuis
VIDA Diagnostics, Inc.
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Instagram

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.